Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. Yu SC, Hui JW, Hui EP, Chan SL, Lee KF, Mo F, et al. Radiology. 2014 Feb;270(2):607-20. doi: 10.1148/radiol.13130498. Epub 2013 Oct 28. PMID: 24126369.

Advances in the interventional therapies for Hepatocellular Carcinoma. Cho CC, Hui JW, Yu SC. From inflammation to cancer: advances in diagnosis and therapy for gastrointestinal and hepatological diseases. Singapore: World Scientific Publishing Company; c2012. Chapter 9, Advances in the interventional therapies for hepatocellular carcinoma; p. 205-219.

Embolization efficacy and treatment effectiveness of transarterial therapy for unresectable hepatocellular carcinoma: a case-controlled comparison of transarterial ethanol ablation with lipiodol-ethanol mixture versus transcatheter arterial chemoembolization. Yu SC, Hui JW, Hui EP, Mo F, Lee PS, Wong J, et al. J Vasc Interv Radiol. 2009 Mar;20(3):352-9. doi: 10.1016/j.jvir.2008.12.407. Epub 2009 Jan 23. PMID: 19167240.

A comparison of three transarterial lipiodol-based formulations for hepatocellular carcinoma: in vivo biodistribution study in humans. Yu SC, Leung TW, Lau WY, Lee N, Hui EP, Yeo W, et al. Cardiovasc Intervent Radiol. 2008 Mar-Apr;31(2):289-98. doi: 10.1007/s00270-007-9173-8. Epub 2007 Oct 10. PMID: 17926090.

Transarterial ethanol ablation of hepatocellular carcinoma with lipiodol ethanol mixture: phase II study. Yu SC, Hui EP, Wong J, Wong H, Mo F, Ho SS, et al. J Vasc Interv Radiol. 2008 Jan;19(1):95-103. doi: 10.1016/j.jvir.2007.08.038. PMID: 18192473.